|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
This arrest in metastatic potential of breast cancer cells suggests the contribution of ERβ in the induction of a more aggressive phenotype in MDA-MB-231 breast cancer cells.
|
28797712 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Together with estrogen receptors ERα and ERβ, the G protein-coupled estrogen receptor (GPER) mediates important pathophysiological signaling pathways induced by estrogens and is currently regarded as a promising target for ER-negative (ER-) and triple-negative (TN) breast cancer.
|
28520140 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
|
28376210 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
On the other hand, it has been recently shown that knockdown of the estrogen receptor α (ERα) in low invasive MCF-7 (ERα+) breast cancer cells and the suppression of ERβ in highly aggressive MDA-MB-231 (ERβ+) cells significantly alter the functional properties of breast cancer cells and the gene expression profile of matrix macromolecules related to cancer progression and cell morphology.
|
28332606 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy-Treated Patients-Results from a Population-Based Breast Cancer Cohort.
|
27810901 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we examine the impact of ERβ on the ERα-p53 loop in breast cancer.
|
28577282 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we examined the expression of the estrogen receptor β (<i>ER</i>β) gene in breast cancer and its relevance in neoadjuvant therapy.
|
28454303 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present review focuses on the tumor suppressive role of ERβ, and the efficacy and mechanisms of several natural and synthetic ERβ agonists against breast cancer.
|
29096893 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor beta (ERβ) is endowed with oncosuppressive activities, antagonizing hormone-induced carcinogenesis and inhibiting growth and oncogenic functions in luminal-like breast cancers (BCs), where its expression correlates with a better prognosis of the disease.
|
29017520 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Bisphenol AF as an Inducer of Estrogen Receptor β (ERβ): Evidence for Anti-estrogenic Effects at Higher Concentrations in Human Breast Cancer Cells.
|
29093337 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Increasing evidence has indicated an important role for estrogen receptor beta 1 (ERβ1) in breast cancer.
|
28583190 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, when combined with MSI/LOH in AR, ERβ and CYP19 genes, we were able to detect significant associations with the GSTP1 wild-type genotype in PR (progesterone receptor) negative breast cancers or the CYP17 wild-type genotype in ER (estrogen receptor) and PR-negative breast tumors.
|
28692125 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Co-expression of ERα and ERβ was associated with breast cancer aggressiveness, including higher histological grade and positive nodal status, which commonly occur following the menopause.
|
28808484 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of estrogen receptor beta (ERβ) in breast cancer cells is associated with epithelial maintenance, decreased proliferation and invasion, and a reduction in the expression of the receptor has been observed in invasive breast tumors.
|
28673316 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Nuclear receptors such as the estrogen receptors (ERα and ERβ) modulate the effects of the estrogen hormones and are important targets for design of innovative chemotherapeutic agents for diseases such as breast cancer and osteoporosis.
|
28858267 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
It occurs at a younger age and bears similarities at the molecular level to pre-menopausal breast cancer in white women, with remarkably lower levels of ERβ expression.
|
26730581 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The results demonstrated that NaAsO2 dose-dependently increased viability of hormone-dependent breast cancer MCF-7 and T47D cells expressing both ERα and ERβ but not hormone-independent MDA-MB-231 cells expressing ERβ.
|
25728338 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
We searched Medline, Embase, and the Web of Science for studies published between 1990 and 2015 that assessed ERβ status in breast cancer patients.
|
26863572 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
GEN exerts its functions through its interaction with the estrogen receptors (ER), ERα and ERβ, and we previously reported that the ERα/ERβ ratio is an important factor to consider in GEN-treated breast cancer cells.
|
26100284 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data clearly show that ERβ plays a crucial role in the cell behavior and ECM composition of the highly aggressive MDA-MB-231 cells and opens a new area of research to further understand its role and to improve pharmaceutical targeting of the non-hormone dependent breast cancer.
|
27179695 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We aimed to evaluate the impact of ER-β expression on breast cancer survival.
|
26902609 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
DNA was isolated and genotyped for six ESR1 and two ESR2 single-nucleotide polymorphisms (SNPs) from tumor specimens from 3691 postmenopausal women with hormone receptor-positive breast cancer enrolled in the BIG 1-98 trial to receive tamoxifen and/or letrozole for 5 years.
|
26590813 |
2015 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The ERβ stabilization effects of Dip G may enable the development of ERβ-targeted therapies for human breast cancers.
|
26670079 |
2015 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the conduct of studies of endometrial ERβ expression needs to be standardized: agreement is needed regarding the most appropriate control tissue for endometrial cancer studies as well as development of standardized methods for the quantification of ERβ immunohistochemical data, similar to those scoring systems employed for other hormonally regulated tissues such as breast cancer, since these data may have direct clinical implications in guiding therapy.
|
25305176 |
2015 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to determine the impact of obesity on breast cancer cell ERβ expression, which is currently unknown.
|
26709918 |
2015 |